Teva's SD-809 passes latest tardive dyskinesia test

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said two doses of SD-809 deutetrabenazine met the primary endpoint in the Phase III AIM-TD study to treat moderate to severe tardive dyskinesia. The company intends to submit

Read the full 331 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE